Jamie Eberling



Link to group website: Website


Dr. Eberling received her PhD from the University of California at Berkeley and did her post-doctoral training in PET imaging at the Lawrence Berkeley National Laboratory. Prior to joining the Michael J. Fox Foundation in 2009, she did research using PET imaging to study Alzheimer’s disease and Parkinson’s disease and was involved in the development and translation of gene therapy approaches for Parkinson’s disease using AADC PET imaging as a readout for therapeutic response to AAV-AADC gene therapy first in primate studies and then in a Phase 1 clinical trial. She also worked on the preclinical development of AAV-GDNF gene therapy for Parkinson’s disease. At the Michael J. Fox Foundation (MJFF), Dr. Eberling has been involved in a number of different programs over the years. She led the cognition program including the first and only Phase 1 therapeutic trial sponsored by MJFF for PD-MCI. Most notably, Dr. Eberling has overseen the PET imaging program since 2009 and launched the Foundation’s dedicated effort to developing a selective alpha-synuclein PET tracer in 2010. Since that time, MJFF has funded tens of millions of dollars toward this effort and in 2016 Dr. Eberling announced a 2 million dollar prize to the first group to develop a selective alpha-synuclein PET tracer. Although the prize has yet to be awarded much progress has been made and MJFF hopes to award the prize in the near future.  Dr. Eberling is now the head of the Research Resources Department which includes imaging (PET and MRI), laboratory tools (reagents and antibodies), data, biospecimens , and open access publications. She continues to lead the PET tracer development program with a focus on the development of novel PET tracers for a variety of different pathological and therapeutic targets.